Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15527772 | 0.98 | LMNA (0.41) | LMNAHSD17B10HPGDMAPTAOC3 | |
| SCHEMBL20557567 | 0.79 | ALDH1A1 (0.45) | ALDH1A1NOS3NOS1NOS2KMT2A | |
| SCHEMBL4790717 | 0.79 | POLB (0.47) | MAPTL3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL29377685 | 0.79 | POLB (0.47) | MAPTL3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL22235444 | 0.79 | HSD17B10 (0.52) | LMNAHSD17B10HPGDMAPTAOC3 | |
| SCHEMBL21223170 | 0.78 | KDM4E (0.39) | HPGDAOC3NOS3NOS1NOS2 | |
| SCHEMBL17404964 | 0.77 | SLC6A2 (0.44) | LMNAHSD17B10HPGDMAPTAOC3 | |
| SCHEMBL24584512 | 0.76 | MCHR1 (0.42) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL29640685 | 0.76 | MCHR1 (0.42) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL16055075 | 0.76 | TSHR (0.43) | LMNAHSD17B10HPGDMAPTAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2025-02-06 | — | — | US | disclosed |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| CN-110023290-B | Heteroaryl carboxamide compounds as RIPK2 inhibitors | 勃林格殷格翰国际有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220081437-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2022-03-17 | — | — | US | disclosed |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| EP-3512833-B1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3512833-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | Boehringer Ingelheim International GmbH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-10138241-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| WO-2018052772-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | LMNA 1443/4885HSD17B10 1657/4885HPGD 1513/4885 |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | LMNA 1266/4885HSD17B10 1745/4885HPGD 1633/4885 |
| US-10138241-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | LMNA 1083/4885HSD17B10 2308/4885HPGD 2454/4885 |
| US-20220081437-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | LMNA 1266/4885HSD17B10 1745/4885HPGD 1633/4885 |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | LMNA 1083/4885HSD17B10 2308/4885HPGD 2454/4885 |
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | LMNA 1443/4885HSD17B10 1657/4885HPGD 1513/4885 |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | RIPK2, RIPK4, RIPK1 | LMNA 2399/4885HSD17B10 2020/4885HPGD 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.